- Home
- SEVN vs DRUG Comparison
SEVN vs DRUG Comparison
Compare SEVN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- DRUG
- Stock Information
- Founded
- SEVN 1986
- DRUG 2019
- Country
- SEVN United States
- DRUG United States
- Employees
- SEVN N/A
- DRUG N/A
- Industry
- SEVN Real Estate Investment Trusts
- DRUG Pharmaceuticals and Biotechnology
- Sector
- SEVN Real Estate
- DRUG Health Care
- Exchange
- SEVN Nasdaq
- DRUG Nasdaq
- Market Cap
- SEVN 173.7M
- DRUG 199.7M
- IPO Year
- SEVN N/A
- DRUG N/A
- Fundamental
- Price
- SEVN $12.85
- DRUG $28.37
- Analyst Decision
- SEVN Strong Buy
- DRUG Strong Buy
- Analyst Count
- SEVN 3
- DRUG 7
- Target Price
- SEVN $14.75
- DRUG $83.25
- AVG Volume (30 Days)
- SEVN 48.7K
- DRUG 56.6K
- Earning Date
- SEVN 07-28-2025
- DRUG 08-13-2025
- Dividend Yield
- SEVN 10.89%
- DRUG N/A
- EPS Growth
- SEVN N/A
- DRUG N/A
- EPS
- SEVN 1.15
- DRUG N/A
- Revenue
- SEVN $30,074,000.00
- DRUG N/A
- Revenue This Year
- SEVN $7.45
- DRUG N/A
- Revenue Next Year
- SEVN $1.12
- DRUG N/A
- P/E Ratio
- SEVN $11.18
- DRUG N/A
- Revenue Growth
- SEVN N/A
- DRUG N/A
- 52 Week Low
- SEVN $10.18
- DRUG $0.93
- 52 Week High
- SEVN $14.66
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- SEVN 64.41
- DRUG 52.64
- Support Level
- SEVN $11.78
- DRUG $23.18
- Resistance Level
- SEVN $12.77
- DRUG $26.86
- Average True Range (ATR)
- SEVN 0.28
- DRUG 1.90
- MACD
- SEVN 0.08
- DRUG 0.24
- Stochastic Oscillator
- SEVN 78.26
- DRUG 84.13
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.